The best magazine
Genetic Test : Health & Medical
Arguments abound for next-generation sequencing technologies to replace genome-wide association studies, but a pair of studies may breathe new life into the old tried and true.
Can variability in drug response and in complication occurrence with pharmacologic therapies for Parkinson's disease be explained by genetic factors?
Do treatment outcomes of tamoxifen for breast cancer differ according to CYP2D6 genotype?
Dr. Andrew Wilner reviews current data on the clinical benefit of HLA-B*1502 screening to avoid carbamazepine-related hypersensitivity.
Tumor angiogenesis genotyping in metastatic gastric cancer patients may help identify a patient subgroup unlikely to benefit from a platinum-based chemotherapeutic regimen.
Inflammation plays a key role in Alzheimer disease, and dissecting the genetics of inflammation may provide an answer to the possible treatment.
Advances in the speed and scale of DNA sequencing means it's now practical to produce personalized clinical evaluations. What impact will this have on pharmacogenomics and medicine as a whole?
What insights can pharmacogenetic studies give us as to the various phenotypes of COPD and their differing responses to currently existing and future therapies?
This review explores the pharmacogenetics surrounding chemotherapeutic protocols in pediatric ALL, with a focus on markers which might predict treatment resistance and toxicity.
Dr. Maurie Markman reviews current data on the clinical utility of CYP2D6 testing for breast cancer patients taking tamoxifen.
Does the presence of polymorphisms in certain genes and alterations in their miRNA expression affect in vitro chemosensitivity to cisplatin and gemcitabine?
Dr. Michael Davidson discusses how a study looking at a genetic cause of elevated homocysteine levels might explain some of the links between homocysteine, folic acid supplementation, and CHD risk.
Dr. Gary Small discusses the potential clinical application of recent findings on cerebrospinal fluid genetic markers for Alzheimer disease.
Why do older adults have varied and complex responses to psychotropic medications?
Dr. Daniel Kuritzkes reviews current data on the clinical benefit of HLA-B*5701 testing to prevent abacavir hypersensitivity reaction.
Will pharmacogenetics open a new era in stroke therapy? This review summarizes candidate gene and genome-wide studies aimed at discovering genetic stroke risk factors and subclinical phenotypes.
Drs. Dermot McGovern and Gil Melmed comment on a study published in Nature on the ability of an IL-28B polymorphism to predict sustained viral response to hepatitis C treatment.
CYP2D6 is crucial for the metabolism of many drugs, but currently phenotyping requires administration of a probe drug. Could a urinary biomarker provide a noninvasive method of CYP2D6 phenotyping?